Effect of canagliflozin on white blood cell counts in patients with type 2 diabetes and heart failure: A subanalysis of the randomized CANDLE trial.

Atsushi TanakaTakumi ImaiMichio ShimabukuroIkuko NakamuraKazuo MatsunagaYukio OzakiTohru MinaminoMasataka SataKoichi Nodenull null

Published in: Journal of diabetes investigation (2022)

Our findings suggest that 24 weeks of treatment with canagliflozin, relative to glimepiride, reduced WBC counts in patients with type 2 diabetes and heart failure.

Keyphrases

heart failure
phase iii
phase ii
open label
left ventricular
double blind
peripheral blood
single cell
study protocol
atrial fibrillation
cardiac resynchronization therapy
placebo controlled
acute heart failure
cell therapy
gestational age